Abstract. Deoxypodophyllotoxin (DPT), a naturally occurring flavolignan, has a broad range of biological effects, including anti-inflammatory, anti-viral and anticancer properties. The present study investigated the anti-proliferative effect of DPT on human cholangiocarcinoma QBC939 and RBE cell lines and its underlying mechanisms of inducing cytotoxicity. MTT assays demonstrated that DPT inhibited the viability of the QBC939 and RBE cells in a dose and time-dependent manner. In addition, DPT treatment resulted in G2/M phase cell cycle arrest associated with the downregulation of Cyclin B and cyclin dependent kinase 1 and caused an increase in apoptosis that was confirmed by characteristic morphological changes. Apoptosis was accompanied by increasing B-cell lymphoma-2 (Bcl-2)/Bcl-2 associated X protein ratios and activated expression of caspase-3, -8 and -9. These findings suggested that DPT may be a novel anticancer agent against human cholangiocarcinoma.
Introduction
Cholangiocarcinoma is the second most common type of primary liver malignancy globally (1) , accounting for ~3% of gastrointestinal tumors and 10-25% of all hepatobiliary malignancies. The incidence rate of cholangiocarcinoma is increasing, particularly that of intrahepatic cholangiocarcinoma (2) . However, despite advances in imaging, diagnosis and surgical techniques, the 5-year overall survival rate for cholangiocarcinoma is only 20-40% following potentially curative surgery, while the median survival period is 22 months (3) .
Natural products and their derivatives are valuable chemical resources that may be used in the treatment and prevention of cancer (4) . Deoxypodophyllotoxin (DPT), an analog of podophyllotoxin isolated from Anthriscussylvestris roots, has been extensively studied due to its multiple pharmacological activities. DPT exhibits antitumor effects on HeLa cells, glioblastoma and non-small cell lung, gastric and breast cancer (5-13), anti-inflammatory (14) and anti-viral (15) activities. There is an increasing amount of evidence demonstrating that DPT inhibits proliferation in cultured cancer cells by inducing apoptosis and or cell cycle arrest (8) (9) (10) (11) (12) (13) .
To the best of our knowledge, the present study is the first of its kind to examine the antitumor effect of DPT on human cholangiocarcinoma cells, including its effects on cellular growth and apoptosis rate, as well as the underlying mechanisms.
Materials and methods

Materials. DPT was purchased from Yunnan Xili Pharmaceutical
Company (Kunming, China). The human cholangiocarcinoma QBC939 and RBE cell cells were purchased from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). All cell culture reagents were obtained from Gibco; Thermo Fisher Scientific, Inc. (Waltham, MA, USA). An Annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit and propidium iodide (PI)/RNase staining buffer were purchased from Calbiochem (EMD Millipore, Billerica, MA, USA). MTT, dimethyl sulfoxide (DMSO), Hoechst 33258, and antibodies were obtained from Sigma-Aldrich; Merck KGaA (Darmstadt, Germany).
Cell lines. The human cholangiocarcinoma QBC939 and RBE cell lines were cultured in RPMI-1640 medium, supplemented with 10% (v/v) heat-inactivated fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 µg/ml). The cultures were maintained in a 5% CO 2 humidified atmosphere at 37˚C.
Growth inhibitory evaluation. The MTT growth inhibition method was used to assess the cytotoxicity of DPT as described previously (16 20 µl MTT dye solution (5 mg/ml in phosphate buffer; pH 7.4) was added to each well and the cells were incubated for an additional 4 h, prior to the addition of DMSO for color development. Metabolic activity was quantified by measuring light absorbance at 570 nm (17) .
Flow cytometry for cell cycle analysis. Following a 24 h incubation at 37˚C to allow for attachment, QBC939 and RBE cholangiocarcinoma cells (1x10 6 cells/well) were seeded in 6-well plates and treated with DPT for 48 h in a concentration range of 0-1 µM. The cells were washed with PBS (pH 7.4) and fixed with 80% ice-cold ethanol at 4˚C overnight. The cells were subsequently treated with 80 mg/ml RNase and 50 mg/ml PI in the dark for 30 min, and analyzed using a Coulter Epics XL Flow Cytometer (Beckman Coulter, Inc., Miami, FL, USA).
Hoechst 33258 staining. A fluorescent morphological assay (18) was performed to detect the apoptosis induced by DPT. In total, 1x10 6 cells were seeded in 6-well plates and allowed to attach overnight. Thereafter the cells were treated with 0.5 µM DPT or solvent control (Fresh medium without serum) for 48 h. The cells were subsequently washed twice with PBS and fixed using 4% formaldehyde for 15 min. Subsequently, cells were washed in PBS and stained with 50 µl of Hoechst 33258 solution (50 ng/ml in PBS; Sigma-Aldrich; Merck KGaA) for 15 min at 4˚C in the dark and subsequently examined using an Olympus FV1000 fluorescent microscope (Olympus Corporation, Tokyo, Japan) at 356 nm.
Analysis of apoptosis. Induction of apoptosis by DPT was assessed by the binding of Annexin V to phosphatidylserine, which is externalized to the outer leaflet of the plasma membrane early during the induction of apoptosis. For Annexin V-FITC binding, QBC939 and RBE cells were treated with DPT for 48 h, harvested and resuspended in the binding buffer provided in the Annexin V-FITC apoptosis detection kit. Cells were reacted with 5 µl Annexin V-FITC reagent and 5 µl PI for 30 min at room temperature in the dark. Stained cells were analyzed by flow cytometry.
Western blot analysis. Following treatment with 0, 0.05, 0.1, 0.5 or 1 µM DPT for 48 h, the cells were washed twice with PBS, and lysed using radioimmunoprecipitation assay buffer (20 mM Tris, pH 7.5; 150 mM NaCl; 1% Triton X-100; 2.5 mM sodium pyrophosphate; 1 mM EDTA; 1% Na 3 CO 4 ; 0.5 g/ml leupeptin; 1 mM phenylmethanesulfonyl fluoride) on ice to obtain the protein. Lysates were subsequently centrifuged at 13,400 x g for 15 min at 4˚C. The supernatant was collected and total protein concentrations were measured using a bicinchoninic acid assay (Pierce; Thermo Fisher Scientific, Inc.). Mitochondria and cytosol were separated by differential ultracentrifugation (19) . A total of 30 µg protein lysate was separated by 10% SDS-PAGE and electrophoretically transferred to a polyvinylidene difluoride membrane (Immunobilon-P, 0.45 mm; EMD Millipore, Billerica, MA, USA) using the TE 77 Semi-Dry Transfer Unit (GE Healthcare Life Sciences, Buckinghamshire, UK). The blot was blocked in blocking buffer (5% non-fat dry milk; 1% Tween-20 in PBS) for 1 h at room temperature, incubated with the following specific primary antibodies: Cyclin B (cat no. sc-166210), cyclin-dependent kinase 1 (CDK1; cat no. sc-53219), Bcl-2 associated X protein (Bax; cat no. sc-80658), B-cell lymphoma-2 (Bcl-2; cat no. sc-509), cleaved caspase-3 (cat no. sc-271759), cleaved caspase-8 (cat no. sc-5263), cleaved caspase-9 (cat no. sc-17784) and β-actin (all the primary antibodies were purchased from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) at a dilution of 1:1,000 overnight at 4˚C. Subsequently, blots were incubated with the corresponding horseradish peroxidase conjugated secondary antibody (cat no. sc-2350, Santa Cruz Biotechnology, Inc.) at a dilution of 1:2,000 for 1 h at room temperature. The signal was visualized with the Enhanced Chemiluminescence Plus detection system (GE Healthcare Life Sciences, Shanghai, China). Protein bands were semi-quantified by densitometric analysis using ImageJ 1.43 software (National Institutes of Health, Bethesda, MA, USA). The densitometry readings of the bands were normalized according to β-actin expression.
Statistical analysis. All experiments were repeated ≥3 times. The data are presented as the mean ± standard deviation and processed using SPSS software (version 13.0; SPSS Inc., Chicago, IL, USA). Statistical analyses were performed using either an unpaired or two-tailed Student's t-test or one-way analysis of variance. Post-hoc analysis between the groups was performed using Student-Newman-Keuls method. P<0.05 was considered to indicate a statistically significant difference.
Results
DPT inhibits the viability of QBC939 and RBE cells.
The growth inhibition effect of DPT on QBC939 and RBE cellular viability was determined using an MTT assay. As presented in Fig. 1 , DPT induced a dose and time-dependent inhibition of the cellular viability of QBC939 and RBE cells following the treatment in vitro. The 50% growth inhibition concentration (IC 50 ) of QBC939 was estimated to be 1.186, 0.779 and 0.460 µM for 24, 48 and 72 h, respectively. The IC 50 of RBE was estimated to be 1.138, 0.726 and 0.405 µM for 24, 48 and 72 h, respectively.
DPT induced G2/M phase arrest in QBC939 and RBE cells.
The effect of DPT on cell cycle profile was analyzed using flow cytometry. QBC939 and RBE cells were treated with 0, 0.05, 0.1, 0.5 and 1 µM of DPT for 48 h and their distribution in the different phases of the cell cycle was calculated. The population of cells in G2/M phase increased and that in S phase decreased in a dose-dependent manner. For the QBC939 cells, the percentage of cells in S phase decreased from 61.5±5.9 to 29.3±7.3%, while those in G2/M phase increased from 11.5±2.9 to 49.1±5.6% (Table I) . For the RBE cells, the percentage of cells in S phase decreased from 61.4±6.1 to 35.5±4.7%, while those in G2/M phase increased from 12.0±2.4 to 46.7±4.4% (Table II) .
Morphological changes caused by DPT. Control and DPT treated cells were stained with the fluorescent dye Hoechst 33528 and visualized using a fluorescent microscope. The control cells were normal, and the nuclei were round and homogeneous ( Fig. 2A), whereas QBC939 (Fig. 2B) and RBE (Fig. 2C ) cells treated with DPT exhibited cell shrinkage, chromatin condensation and nuclear deformation and disassembly, which are all features indicative of apoptosis.
Effects of DPT on QBC939 and RBE cell apoptotic induction.
The effects of DPT on cellular apoptosis were analyzed using flow cytometry. Subsequent to QBC939 and RBE cells being treated with various concentrations of DPT for 48 h, cells were stained with Annexin V-FITC and PI. As presented in Fig. 2D , the percentage of Annexin V-FITC binding QBC939 cells treated with DPT increased in a concentration-dependent manner from 17% at 0.05 µM DPT to 60% at 1 µM DPT. As shown in Fig. 2E , the percentage of Annexin V-FITC binding RBE cells treated with DPT increased in concentration-dependent manner from 19% at 0.05 µM DPT to 68% at 1 µM DPT.
Effects of DPT on cell cycle regulators. In order to reveal the mechanisms underlying the G2/M arrest observed subsequent to the addition of DPT, western blotting was used to determine the expression levels of cell cycle-regulating proteins including Cyclin B1 and CDK1. The present results revealed that DPT treatment resulted in a significant reduction in the protein levels of Cyclin B1 and CDK1 in a dose dependent manner (Fig. 3) .
Effects of DPT on apoptosis regulators.
To examine the mechanisms underlying the apoptosis observed following the addition of DPT, western blot analysis was used to determine the expression levels of apoptosis-associated proteins including Bax, Bcl-2, cleaved caspase-3, -8 and -9. DPT treatment resulted to a significant reduction in the protein levels of cleaved caspase-3, -8, and -9 in a dose-dependent manner (Fig. 3) . In addition, the expression level of Bax in DPT-treated cells was greatly increased, and accompanied by the downregulation of Bcl-2 expression levels (Fig. 3) . Therefore, the ratios of Bax/Bcl-2 were notably increased in a dose-dependent manner.
Discussion
DPT has been widely used to treat numerous diseases due to its anti-inflammatory and antitumoral effects (5-13). However, the effect of DPT on human cholangiocarcinoma cells remains unclear. The present study demonstrated that DPT exhibited a significantly inhibitory effect on the prolif- respectively. Additional analysis revealed that DPT exerted clear cytotoxic activity against human cholangiocarcinoma cells, primarily via cell cycle arrest at the G2/M phase associated with the decrease of the Cyclin B1 and CDK1 and apoptosis induction, which was verified by the typical apoptotic morphological changes and the significant increase in apoptotic cell populations. The present study also identified that the apoptosis of cholangiocarcinoma cells induced by DPT involves intrinsic and extrinsic pathways.
It is known that cellular growth and proliferation of mammalian cells are mediated by cell cycle progression. Furthermore, inhibition of the cell cycle has become an effective strategy for eliminating cancer cells (20) . The results of the present study demonstrated that the percentage proportion was reduced in the S phase cells and increased in the G2/M phase cells following treatment with DPT in a dose-dependent manner, indicating that the inhibitory effect of DPT on QBC939 and RBE cellular proliferation is mediated by G2/M phase cell cycle arrest. Previously, DPT was reported to induce inhibition of growth via cell cycle arrest in the G2/M phase of different cancer cell lines including HeLa leukemia (8-9) and non-small cell lung (10), gastric (11) and breast cancer (12) and glioblastoma (13) cells which is consistent with the results obtained in the present study.
It is known that cyclin protein and cyclin-dependent kinase (CDK) are two major components in cell cycle regulation (9) , which can combine into the activated cyclin-CDK kinase complex to promote cell cycle transport. Among CDKs that regulate cell cycle progression, Cyclin B, in association with CDK1, governs cell cycle progression by enhancing cell cycle distribution in the G2/M fraction (21) . Entry into mitosis requires that CDK1/Cyclin B complexes are activated by Cdc25C phosphatase, which removes the inhibitory phosphorylation of CDK1 (22) . To examine the mechanisms by which DPT led to G2/M phase arrest in QBC939 and RBE cells, the present study additionally investigated the status of key factors known to regulate cell cycle progression. The present result srevealed that DPT treatment significantly decreased the expression of Cyclin B1 and CDK1 suggesting that G2/M cell cycle arrest in cholangiocarcinoma cells is caused, at least in part, by changes in the Cyclin B1 and CDK1 protein levels.
Apoptosis is the process of programmed cell death, and is coupled with a number of clear morphological changes and cellular signaling pathways (23) . The activation of apoptosis has been regarded as a target in cancer therapies (24) . The morphological characteristics of apoptosis include condensation of cytoplasm and chromatin, chromosomal DNA fragmentation, and formation of apoptotic bodies (25) . Therefore, the present study used Hoechst 33258 staining and flow cytometric assays to measure DPT induced apoptosis. In DPT-treated QBC939 and RBE cells, typical apoptotic changes of nuclear pyknosis and karyorrhexis are observed by Hoechst 33258 staining. Meanwhile, Annexin V staining results demonstrated that DPT significantly induced the apoptosis of QBC939 and RBE cells in a dose dependent manner (P<0.05). The results therefore suggest that DPT inhibited the proliferation of the QBC939 and RBE cells partially by inducing apoptosis.
In mammalian cells, death receptor induced extrinsic and mitochondria apoptosome mediated apoptotic intrinsic pathways are the two major pathways involved in the initiation of apoptosis (26) . Bcl-2 family members and caspases perform a central role in controlling the two pathways. Mitochondria also perform a critical role in apoptosis induced by chemotherapeutic agents (27) . Apoptosis is often associated with impaired mitochondrial adenine nucleotide exchange, the alternative channels in the mitochondrial outer membrane that permit the transit of adenine nucleotides (28) . This process can be regulated by the Bcl-2 family of proteins that govern the release of cytochrome c from the mitochondria (29) . The increased ratio of Bax/Bcl-2 induces the loss of mitochondrial membrane potential leading to permeability transition and cytochrome c release. Furthermore, cytochrome c activates caspase-9, which cleaves and activates the downstream effect of proteases, including caspase-3, thus triggering apoptosis (30) . The cell death receptor pathway, mediated distinctively through active/cleaved caspase-8, performs an important role in the maintenance of tissue homeostasis. In addition, this pathway is characterized by binding cell death ligands and cell death receptors, and subsequently activates caspase-8, -3, -6 and -7 (31) and cleaved poly ADP-ribose polymerase. A number of studies have shown that DPT induces caspase-mediated apoptosis in a range of cancer cells (8) (9) (10) (11) (12) (13) and affects numerous factors in cellular signal transduction pathways which are linked to the proapoptotic (Bax) and antiapoptotic (Bcl-2) gene (9, 10) . Accordingly, in the present study, the elevated ratio of Bax/Bcl-2 and cleavage of caspase-3, -8 and -9 significantly increased the dose-dependent exposure to DPT. Generally, these findings indicated that intrinsic and extrinsic pathways are involved in DPT induced apoptosis.
In summary, the present results demonstrated, for the first time, that DPT is a potent growth inhibitor of cholangiocarcinoma cells. The growth inhibition is related to the G2/M phase cell cycle arrest associated with the downregulation of Cyclin B1 and CDK1 and the induction of apoptosis via the intrinsic and extrinsic pathways. Thus, these results provide the basis for DPT as a promising agent against cholangiocarcinoma. However, the in vivo experiment and exact molecular mechanisms behind this needs additional investigations.
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